Xarelto Lawsuit Surge Makes Many Question Blood Thinner’s Once-Daily Dosage

January 12, 2016 – – BloodThinnerHelp.com reports on a different lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals in Pennsylvania State Court. While many lawsuits have been filed against these manufacturers regarding the dangers of blood thinning drug Xarelto, this one is notable as it brings up new allegations.

Complaints found within the suit state that the drug’s recommended once-daily dosage is not effective for a full 24-hour time period as indicated. Further details of the suit indicate that the plaintiff suffered from a stroke just four days after beginning to take Xarelto in order to prevent strokes. He was at an increased risk of stroke due to his atrial fibrillation condition.

Xarelto is the first and only blood thinner to offer one pill a day, one-size-fits-all dosing. Other blood thinners require 2 doses of medication each day. After suffering from a stroke, the plaintiff in this particular case filed suit on October 8th of 2015 against the drug manufacturers. His atrial fibrillation, a fairly common heart condition, put him at greater risk for stroke so he was prescribed Xarelto as a preventative measure.

The man’s complaint is the first of its kind, despite the fact that Xarelto has been the topic of an ever-increasing number of lawsuits. Other lawsuits, allege that Xarelto causes increased risk for dangerous uncontrollable bleeding episodes and even death. In this particular suit, however, the plaintiff clearly states that Xarelto proved ineffective in preventing his stroke and may have actually been the cause of it.

Across the U.S., Xarelto has been involved in more than 2,800 lawsuits in federal court as well as over 550 suits in a mass tort group in Philadelphia, Pennsylvania. The drug was approved by the U.S. Food and Drug Administration in 2011 to prevent strokes and blood clots for individuals with atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. Consumers were initially enticed to use Xarelto due to the fact that the drug was much more liberating than traditional blood thinners because didn’t require special diets or regular monitoring by a physician.

One major problem with the revolutionary new blood thinner, however, was that it was released to the market without any corresponding antidote. This simply means that patients with Xarelto in their system who begin to bleed will be unable to get their blood to clot. In these circumstances, the physicians treating these patients are are required to resort to life-saving measures such as blood transfusions.

Traditional blood thinners do not have this issue, which is why they require special diets. They have an available antidote in vitamin K, which means their effects are able to be reversed with vitamin K treatments. If someone using a traditional blood thinner begins to bleed, doctors can treat them with vitamin K and their blood will clot, a potential life-and-death difference in emergency situations.

Federally filed Xarelto lawsuits have been consolidated to form multidistrict litigation number 2592 and are being overseen by the Honorable U.S. District Judge Eldon E. Fallon. As the cases in the MDL await trial, Attorney Joseph Osborne is working to help ensure that anyone suffering after using Xarelto will have the opportunity to explore their legal rights. He offers free consultations to those involved, who may be entitled to significant compensation.

To ask questions, or request additional information on Xarelto lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60007147